BCI study led by Dr Pedro Cutillas featured on Genomeweb

A recently published study* in Molecular and Cellular Proteomics that investigated acute myeloid leukemia cells has been featured on a recent Genomeweb ProteoMonitor newsweekly.

The study led by Dr Pedro Cutillas from the Centre for Cell Signalling at Barts Cancer Institute completed a quantitative phosphoproteomic analysis that suggests resistance to kinase inhibitor therapies in cancer may be keyed by multiple pathways outside those targeted by the drug.

Phosphoproteomics provides large-scale and unbiased information of how active proteins (the products of genes) are in cancer cells.

The results of the study are important for designing therapeutic strategies for personalised cancer medicine. It shows that the testing-methods used for deciding the best course of therapy for each cancer patient will be more effective and accurate in predicting the right combination of drugs, if they are based on information provided by phosphoproteomics data.

For the full news article, please click here.

*Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Alcolea MP, Casado P, Rodriguez-Prados J, Vanhaesebroeck B and Cutillas P. Molecular and Cellular Proteomics 2012 April; 11(4)